Search results
Cheaper competition for Humira is hitting the market, but savings will depend on your insurance
AP Finance via Yahoo Finance· 11 months agoPatients who take the autoimmune disease treatment Humira may see some price relief when several...
AbbVie's Humira gets a U.S. rival, but costs could stay high
Reuters via Yahoo Finance· 1 year agoU.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug...
How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own
Fortune via Yahoo Finance· 1 year agoThe new drug looked so promising—except for that one warning sign. At the American College of...
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
Motley Fool· 11 months agoEarlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first...
Here's What This Drug News Could Mean for AbbVie's Shareholders
Motley Fool· 2 years agoOn May 11, AbbVie (NYSE: ABBV) announced positive top-line results in its phase 3 clinical trial of...
Good news for consumers, bad news for AbbVie as its blockbuster drug Humira faces competition
Chicago Tribune via Yahoo News· 1 year agoCHICAGO — One of the most popular prescription medications in the world is about to face fierce competition in the U.S. — something that could mean lower prices for the drug but a difficult ...
Obesity drugs like Ozempic are costly, but here’s how we’ll save money down the line | Opinion
Fort Worth Star-Telegram via Yahoo News· 10 months agoNew weight loss drugs powerful enough to help obese patients lose up to a fifth of their total body...
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
Motley Fool· 1 year agoAbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of...
Amgen Inc. (NASDAQ:AMGN) Q4 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoAmgen Inc. (NASDAQ:AMGN) Q4 2022 Earnings Call Transcript January 31, 2023 Amgen Inc. misses on...
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
Motley Fool· 2 years agoThe European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently...